IBSRELA achieved 73% revenue growth in 2025, driven by a first-in-class mechanism that addresses the 77% of IBS-C patients who remain symptomatic on secretagogues. Management successfully executed a patient-first strategy for XPHOZAH, maintaining access for all appropriate patients despite the loss of Medicare Part D reimbursement. The company strengthened its intellectual property moat with a new formulation patent for IBSRELA and XPHOZAH that extends protection until 2042. Operational performance ...

U.S. stock futures were mixed this morning, with the Dow futures falling around 0.1% on Friday.Akamai Techs reported quarterly earnings of $1.84 per share which beat the analyst consensus estimate of $1.75 per share. The company reported quarterly sales of $1.095 billion which beat the analyst consensus estimate of $1.076 billion.Akamai Technologies shares dipped 8.8% to $99.94 in pre-market trading.Here are some other stocks moving lower in pre-market trading.Photo via Shutterstock ...

Core Viewpoint - Ardelyx (ARDX) has received a new patent for its oral formulations of tenapanor, which is significant for its commercial products Isbrela and Xphozah, with the patent set to expire on November 26, 2042 [1] Group 1 - The United States Patent and Trademark Office (USPTO) issued U.S. Patent No. 12,539,299 titled "Oral Formulations of Tenapanor" [1] - The patent covers the commercial formulations of Isbrela and Xphozah [1] - The patent will be submitted to the Food and Drug Administration (FDA) for listing in the Approved Drug Products with Therapeutic Equivalence Evaluations for both products [1]

Company Overview - Ardelyx, Inc. (NASDAQ: ARDX) is a biopharmaceutical company focused on developing and commercializing first-in-class gastrointestinal and cardiorenal therapies [3] Financial Updates - TD Cowen raised its price target on ARDX to $13 from $10 while maintaining a Buy rating, following an update to the firm's financial model ahead of ARDX's fourth-quarter results [1] - Jefferies also raised its price target on Ardelyx, Inc. to $15 from $8 and maintained a Buy rating, highlighting the company as one of the most underrated biotech launches [2] Product and Market Potential - Ardelyx's lead product, tenapanor, treats irritable bowel syndrome with constipation (IBS-C) and chronic kidney disease-related conditions [3] - Peak sales for tenapanor are projected at $1.5–$2 billion by 2035, with additional upside if the new 2041 formulation patent proves defendable [2]

Group 1 - Ardelyx, Inc. (NASDAQ:ARDX) is recognized as a promising small-cap stock with significant growth potential, with analysts raising price targets and maintaining buy ratings [1][4] - The company's Ibsrela revenue showed impressive growth, increasing 73% year-over-year to $274 million in fiscal 2025, and 10% quarter-over-quarter in Q4 2025 to $87 million [2] - For fiscal 2026, Ardelyx projects Ibsrela revenue between $410 million and $430 million, indicating a year-over-year growth of 50% to 58%, with peak sales expected to exceed $1 billion by 2029 [3] Group 2 - Analysts from BTIG and Jefferies have both reiterated buy ratings on Ardelyx, with Jefferies raising the price target from $8 to $15 and BTIG from $14 to $17, reflecting strong confidence in the company's future performance [1][4] - Ardelyx has a robust commercial portfolio, including Ibsrela for IBS with constipation and XPHOZAH for chronic kidney disease patients, indicating a focus on addressing unmet medical needs [5]

Core Insights - Ardelyx, Inc. (NASDAQ:ARDX) is recognized as a fast-growing small-cap stock, with analysts providing positive ratings and price targets [1][2][3] Financial Performance - For fiscal Q3 2025, Ardelyx reported revenue of $110.33 million, reflecting a year-over-year growth of 12.3%, exceeding estimates by $9.78 million [2] - The company's EPS was $0.00, surpassing estimates by $0.07 [2] - Revenue growth was significantly driven by a 92% year-over-year increase in IBSRELA revenue, which reached $78.2 million, exceeding estimates by $7 million [2] Product Performance - The strong performance of IBSRELA is attributed to sustained demand from IBS-C patients for a differentiated treatment option [2] - Management has raised the revenue guidance for IBSRELA, expecting it to be between $270 million and $275 million for 2025 [2] Analyst Ratings - Julian Harrison from BTIG reiterated a Buy rating on Ardelyx with a price target of $14 [1] - Allison Bratzel from Piper Sandler raised the price target from $9 to $10 while maintaining a Hold rating [1][3] - Bratzel noted that the growth in IBSRELA demonstrates the strength of the company's sales force [3]

Core Insights - U.S. stock futures are down, with Dow futures dropping over 300 points [1] - Insperity Inc reported disappointing third-quarter results, leading to a significant drop in its stock price [1][2] Company Performance - Insperity reported a quarterly loss of $0.20 per share, missing the analyst consensus estimate of $0.22 per share [2] - Quarterly sales for Insperity were $1.623 billion, falling short of the analyst consensus estimate of $1.632 billion [2] - Insperity's shares fell 31.3% to $31.00 in pre-market trading following the earnings report [2] Other Companies Impacted - Sarepta Therapeutics Inc saw a decline of 38.7% to $14.98 after reporting third-quarter results and failing to achieve statistical significance in its ESSENCE study [4] - Jeld-Wen Holding Inc's shares dropped 28.1% to $3.02 after reporting worse-than-expected third-quarter results and cutting FY25 guidance [4] - Ichor Holdings Ltd experienced a 26.2% decline to $16.77 after mixed third-quarter results and below-estimate fourth-quarter guidance [4] - Atlas Energy Solutions Inc's shares dipped 17.8% to $10.40 after reporting disappointing third-quarter results [4] - Navitas Semiconductor Corp fell 15.7% to $10.32 following its third-quarter results [4] - Uniqure NV's shares decreased 11.6% to $30.30 after a significant drop of 49% on Monday due to FDA concerns regarding its AMT-130 data [4] - Other companies like Ardelyx Inc, Genius Sports Limited, IAC Inc, and Archer-Daniels-Midland Company also reported declines in pre-market trading due to worse-than-expected financial results or lowered guidance [4]

Core Insights - U.S. stock futures are down, with Dow futures dropping over 300 points [1] - Insperity Inc reported disappointing third-quarter results, leading to a significant drop in its stock price [1][2] Company Performance - Insperity reported a quarterly loss of $0.20 per share, missing the analyst consensus estimate of $0.22 per share [2] - Quarterly sales for Insperity were $1.623 billion, falling short of the analyst consensus estimate of $1.632 billion [2] - Insperity's shares fell 31.3% to $31.00 in pre-market trading following the earnings report [2] Other Companies Impacted - Sarepta Therapeutics Inc saw a 38.7% drop to $14.98 after reporting third-quarter results and failing to achieve statistical significance in its ESSENCE study [4] - Jeld-Wen Holding Inc's shares fell 28.1% to $3.02 after reporting worse-than-expected third-quarter results and cutting FY25 guidance [4] - Ichor Holdings Ltd's shares dipped 26.2% to $16.77 after mixed third-quarter results and below-estimate fourth-quarter guidance [4] - Atlas Energy Solutions Inc's shares decreased by 17.8% to $10.40 after disappointing third-quarter results [4] - Navitas Semiconductor Corp fell 15.7% to $10.32 following its third-quarter results [4] - Uniqure NV's shares dipped 11.6% to $30.30 after a significant drop of 49% on Monday due to FDA concerns regarding its AMT-130 data [4] - Other companies like Ardelyx Inc, Genius Sports Limited, IAC Inc, and Archer-Daniels-Midland Company also experienced declines in pre-market trading due to poor financial results or lowered guidance [4]

Core Insights - Upwork Inc reported better-than-expected third-quarter financial results, with earnings of 36 cents per share, surpassing the Street estimate of 29 cents per share [1] - The company's quarterly revenue reached $201.73 million, exceeding the analyst consensus estimate of $193.34 million [1] - Upwork raised its fourth-quarter guidance above estimates and also increased its FY25 guidance [1] Stock Performance - Upwork shares surged 22.2% to $19.10 in pre-market trading following the positive financial results [2] - Other notable stock movements included PTL Ltd gaining 67.4%, MSP Recovery Inc rising 56.9%, and Denny's Corp increasing by 49.2% due to acquisition news [5] - Conversely, Sarepta Therapeutics Inc saw a significant decline of 38.7% after reporting disappointing third-quarter results [5]

Core Insights - U.S. stocks experienced an upward trend, with the Nasdaq Composite increasing by approximately 1% on Friday [1] - Cloudflare, Inc. reported better-than-expected third-quarter financial results, leading to a significant rise in its stock price [1][2] Company Performance - Cloudflare's quarterly earnings were 27 cents per share, surpassing the Street estimate of 23 cents [2] - The company's quarterly revenue reached $562.02 million, exceeding the analyst estimate of $544.82 million [2] - Following the earnings report, Cloudflare shares surged by 12.6% to $250.73 [2] Other Notable Stock Movements - AMTD Digital Inc. saw a remarkable 157% increase in its stock price to $4.34 after reporting a 1,085.9% year-over-year revenue increase to $73.2 million for the six months ending April 30 [4] - LexinFintech Holdings Ltd. gained 26% to $4.85, while Brighthouse Financial, Inc. rose 25.4% to $57.28 [4] - Illumina, Inc. surged 21% to $119.88 after reporting third-quarter results above estimates and raising its full-year guidance [4] - Reddit, Inc. shares increased by 17.8% to $229.10 after reporting better-than-expected third-quarter results and issuing optimistic fourth-quarter sales guidance [4] - Amazon.com, Inc. rose 11% to $247.26 following positive quarterly results [4]